Sharekhan's research report on Sumitomo Chemical India
Q3FY23 results were weak as consolidated revenue missed the mark by 4% at Rs. 754 crore (up 7% y-o-y) and OPM of 16% was 228 bps below our estimate. Subdued revenue growth reflects decline in export revenue while miss in OPM was due to gross margin contraction. Operating profit/PAT of Rs. 120 crore/Rs. 90, down/up 5%/2% was 16%11% below our estimate. Domestic revenue grew by 21% y-o-y led by price hike offsetting muted volume while export revenue declined steeply by 29% y-o-y due to de-growth in key export region of LatAm given high channel inventories. Capacity expansions, new product registrations, five proprietary products for the parent to drive a recovery in export revenue growth while market share gain in domestic market would result in industry leading growth for SCIL. Focus on high-margin herbicides/PGR bodes well for margin improvement.
Outlook
A sharp correction of 20% in the stock price from 52-week highs provides good entry opportunity for investors as earnings growth outlook is intact (expect 21% PAT CAGR over FY22-25E) led by leveraging technological capabilities of the parent and a massive opportunity in the CRAMS space. We maintain a Buy on SCIL with a revised PT of Rs. 550. Any strict domestic/foreign regulation on usage of key products could affect growth and valuation.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.